Taken with our data showing strong cooperativity between these agents in rejecting B16-BL6 melanoma, further studies are certainly warranted to assess the safety of using 4-1BB agonist antibody and CTLA-4 blockade in combination. This evidence concerns the gene CTLA4 and melanoma.